Michael Altman's most recent trade in Arya Sciences Acquisition Corp IV - Ordinary Shares - Class A was a trade of 2,647,500 Class B ordinary shares done . Disclosure was reported to the exchange on July 31, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arya Sciences Acquisition ... | Michael Altman | Director, Chief Financial Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 2,647,500 | 0 | - | - | Class B ordinary shares | |
| Arya Sciences Acquisition ... | Michael Altman | Director, Chief Financial Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 1,000,000 | 2,647,500 | - | - | Class B ordinary shares | |
| Arya Sciences Acquisition ... | Michael Altman | Director, Chief Financial Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 499,000 | 0 | - | - | Class A ordinary shares | |
| Nautilus Biotechnology Inc | Michael Altman | Director | 14 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | ||
| Perceptive Capital Solutio... | Michael Altman | Director, Chief Business Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 10.00 per share. | 13 Jun 2024 | 286,250 | 286,250 | - | 10 | 2,862,500 | Class A ordinary shares |
| Lyra Therapeutics Inc | Michael Altman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Michael Altman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option | |
| Nautilus Biotechnology Inc | Michael Altman | Director | 15 Jun 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | ||
| Lyra Therapeutics Inc | Michael Altman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,250 | 7,250 | - | - | Stock Option | |
| Nautilus Biotechnology Inc | Michael Altman | Director | 15 Jun 2022 | 86,467 | 86,467 | - | - | Stock Option (Right to Buy) | ||
| Nautilus Biotechnology Inc | Michael Altman | Director | 09 Jun 2021 | 3,647,500 | 3,647,500 | - | - | Common Stock | ||
| Nautilus Biotechnology Inc | Michael Altman | Director | 09 Jun 2021 | 3,647,500 | 0 | - | - | Class B ordinary shares | ||
| Nautilus Biotechnology Inc | Michael Altman | Director | 09 Jun 2021 | 499,000 | 499,000 | - | - | Common Stock | ||
| Nautilus Biotechnology Inc | Michael Altman | Director | 09 Jun 2021 | 499,000 | 0 | - | - | Class A ordinary shares | ||
| Nautilus Biotechnology Inc | Michael Altman | Director | 09 Jun 2021 | 44,435 | 44,435 | - | - | Stock Option (Right to buy) | ||
| Lyra Therapeutics Inc | Michael Altman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,250 | 7,250 | - | - | Stock Option | |
| Arya Sciences Acquisition ... | Michael Altman | Director, Chief Financial Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 10.00 per share. | 02 Mar 2021 | 499,000 | 499,000 | - | 10 | 4,990,000 | Class A ordinary shares |